Pfizer exercises option granted in 2016 to exclusively license lead immunotherapeutic.
Biotech company AnTolRx is developing targeted antigen-specific therapies based on immune tolerance induction rather than immune suppression for several inflammatory and autoimmune diseases. With its approach, an immunomodulatory aryl hydrocarbon receptor agonist is co-delivered with specific antigens to generate disease-specific Treg cells to treat immunological disorders.
Pfizer has elected to exercise an option it was granted in a June 2016 agreement to license the AnTolRx's lead candidate in type 1 diabetes.
Pfizer will pay AnTolRx an up-front payment (and potential milestone and royalty fees) in exchange for exclusive rights to pursue further optimization, development and potential commercialization of the antigen-specific immunotherapy.
